ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix -Linzagolix, an oral GnRH antagonist, is pending regulatory approval in the U.S. and Europe for the treatment of uterine fibroids- –Financing agreement with JGB Management to fund the planned launch of linzagolix as well as other development and operational expenses– – Amendment of Kissei exclusive license […]
Read More